Precision Medicine & Biomarkers 2018
29th - 30th November 2018, Beijing, China
Attending this Summit will provide you with the opportunity to mix and interact with experts working in all facets of Precision Medicine through the individual, panel and roundtable discussions on offer. It is a Summit not to be missed.
This year’s event will bring together a unique and international mix of large and medium pharmaceutical, biotech and diagnostics companies, leading universities and clinical research institutions, government and national labs, CROs, emerging companies and tool providers—making the conference a perfect meeting-place to share experience, foster collaborations across industry and academia, evaluate emerging technologies and all aspects of the biomarker and diagnostic development process from discovery to translation to commercialization.
The biomarkers market is projected to reach USD 53.34 Billion by 2021 from USD 27.95 Billion in 2016. Growth in the biomarkers market is mainly driven by factors such as increasing diagnostic applications of biomarkers, increasing R&D funding for pharma and biotech companies, increasing number of CROs and low cost of clinical trials in developing countries, the high prevalence of cancer, and new initiatives for biomarker research. On the other hand, high capital investments and low cost-benefit ratio, poorly suited regulatory and reimbursement systems, and technical issues related to sample collection and storage are the major factors restraining the growth of this market.
The Precision Medicine & Biomarkers 2018 provides two days of robust discussions on recent advancements and new strategies for development of new materials for global requirements.
The BioTech Pharma Summit: Precision Medicine & Biomarkers 2018 will be focused on the opportunities and challenges of biomarker research discovery and development in a variety of therapeutic areas such as immune-oncology, neuroscience and cardio vascular disease areas, precision medicine, companion diagnostics, data integration methods, and utilising biomarkers in clinical trials.